EUROPE’S PARTNERSHIP FOR HEALTH

What disease and research areas does IMI support?

Health priorities in the IMI Strategic Research Agenda 2014

- antimicrobial resistance
- osteoarthritis
- cardiovascular diseases
- diabetes
- neurodegenerative diseases
- psychiatric diseases
- respiratory diseases
- immune-mediated diseases
- ageing-associated diseases
- cancer
- rare/orphan diseases
- vaccines

- infectious diseases
- brain disorders
- metabolic disorders
- stem cells
- cancer
- biologicals
- vaccines
- lung diseases
- drug delivery
- drug discovery
- data management
- inflammatory disorders
- geriatrics
- education and training
- sustainable chemistry
- drug safety
- other

Get involved

IMI regularly issues new Calls for proposals, giving researchers from diverse sectors the opportunity to apply to participate in ambitious projects that will pave the way for the development of the medicines of the future.

Simon Lovestone
Professor of Translational Neuroscience
University of Oxford, UK

IMI has really made a change to the way we do our work. Of course it brings an important funding stream but more importantly than that, it brings collaborations with industry. Working with industry colleagues we have gained an incredible amount – ranging from technical expertise, to compounds and reagents to project management with milestone driven programmes.

Breda Flood
President of the European Federation of Allergy and Airways Diseases Patients’ Associations

Participating in IMI projects allows patients to make a very real contribution to research on diseases that affect them. As a partner in the U-BIOPRED project on severe asthma, my voice as a patient was listened to from the outset and patient input proved instrumental in helping the project achieve its goals.

Dimitrios Tzalis
Founder and Chief Executive Officer of Taros Chemicals, Dortmund, Germany
Head of the European Lead Factory Chemistry Consortium

As an SME, participation in IMI’s European Lead Factory project has given us excellent scientific insights and the opportunity to build long-lasting relationships and networks, as well as the opportunity to enhance our skills in areas like people management and consensus building. Furthermore, as an SME with a strong focus on innovation, working with IMI has given extra momentum to our broader activities.

Carlo Incerti
Head of Global Medical Affairs, Genzyme
Member of the IMI Governing Board

IMI has revolutionised the way companies are working on major R&D programs. Where before there were firewalls and diffidence, now we have cross-company teams who are working to address major unmet medical needs.

Carlos Moedas
Commissioner for Science, Research and Innovation
European Commission

Unlocking the potential of public funding is a priority for the European Commission. IMI is one of our biggest success stories. This public-private partnership combines research, technology, innovation and entrepreneurship to speed up the development of treatments against disease and to address the health needs of citizens.

Innovative Medicines Initiative

IMI regularly issues new Calls for proposals, giving researchers from diverse sectors the opportunity to apply to participate in ambitious projects that will pave the way for the development of the medicines of the future.

Simon Lovestone
Professor of Translational Neuroscience
University of Oxford, UK

IMI has really made a change to the way we do our work. Of course it brings an important funding stream but more importantly than that, it brings collaborations with industry. Working with industry colleagues we have gained an incredible amount – ranging from technical expertise, to compounds and reagents to project management with milestone driven programmes.

Breda Flood
President of the European Federation of Allergy and Airways Diseases Patients’ Associations

Participating in IMI projects allows patients to make a very real contribution to research on diseases that affect them. As a partner in the U-BIOPRED project on severe asthma, my voice as a patient was listened to from the outset and patient input proved instrumental in helping the project achieve its goals.

Dimitrios Tzalis
Founder and Chief Executive Officer of Taros Chemicals, Dortmund, Germany
Head of the European Lead Factory Chemistry Consortium

As an SME, participation in IMI’s European Lead Factory project has given us excellent scientific insights and the opportunity to build long-lasting relationships and networks, as well as the opportunity to enhance our skills in areas like people management and consensus building. Furthermore, as an SME with a strong focus on innovation, working with IMI has given extra momentum to our broader activities.

Carlo Incerti
Head of Global Medical Affairs, Genzyme
Member of the IMI Governing Board

IMI has revolutionised the way companies are working on major R&D programs. Where before there were firewalls and diffidence, now we have cross-company teams who are working to address major unmet medical needs.

Carlos Moedas
Commissioner for Science, Research and Innovation
European Commission

Unlocking the potential of public funding is a priority for the European Commission. IMI is one of our biggest success stories. This public-private partnership combines research, technology, innovation and entrepreneurship to speed up the development of treatments against disease and to address the health needs of citizens.
The Innovative Medicines Initiative (IMI) is a partnership between the European Union (EU), represented by the European Commission, and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

IMI is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas of unmet medical or social need. IMI does this by facilitating collaboration between the key players in health research, including universities, pharmaceutical companies, small and medium-sized enterprises (SMEs), patient organisations, and others.

IMI has a total budget of over €5 billion for the period 2008-2024. Half of this comes from the EU’s research and innovation programmes, while the other half comes from EFPIA members as well as some other large organisations and companies.

IMI projects are delivering results that are advancing drug development

Tackling the scourge of antimicrobial resistance: The TRANSLOCATION project has worked out the structure of proteins involved in transporting substances (including, potentially antibiotics) into and out of bacterial cells.

Better clinical trials for Alzheimer’s disease: The EPAD project is pioneering a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s dementia. The ‘adaptive’ trial design should deliver better results faster and at lower cost.

New tools to study diabetes: In a world first, the IMIDIA project developed the world’s first functional line of human pancreatic beta cells (the cells which go wrong in diabetes). These make it easier for scientists to study diabetes in the lab.

Towards safer medicines: The WEB-RADR project has developed a smartphone app that allows patients, carers and healthcare professionals to quickly and easily report side effects of medicines.

Faster drug development: The European Lead Factory has created a unique drug discovery platform that scientists can apply to use for their own research. Users report that the results have significantly accelerated their drug development programmes.

Promoting patient involvement in research: The EUPATI project has compiled an online, multilingual educational toolbox (www.eupati.eu) for patients who want to know more about, or get involved in, medicines research and development.

The IMI community

Stay in touch

www.imi.europa.eu
@IMI_JU
bit.ly/IMInewsletter
bit.ly/LinkedInIMI

IMI projects are delivering results that are advancing drug development

- 2 300 JOBS
- 1 749 PUBLICATIONS
- 20 PATENT APPLICATIONS
- 13 SPIN-OFFS

Stay in touch

www.imi.europa.eu
@IMI_JU
bit.ly/IMInewsletter
bit.ly/LinkedInIMI

The IMI community

| 970 academic / research organisation teams |
| 552 EFPIA teams |
| 202 SME teams |
| 31 patient organisation teams |
| 108 other teams |

IMI projects are delivering results that are advancing drug development

- Tackling the scourge of antimicrobial resistance: The TRANSLOCATION project has worked out the structure of proteins involved in transporting substances (including, potentially antibiotics) into and out of bacterial cells.
- Better clinical trials for Alzheimer’s disease: The EPAD project is pioneering a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s dementia. The ‘adaptive’ trial design should deliver better results faster and at lower cost.
- New tools to study diabetes: In a world first, the IMIDIA project developed the world’s first functional line of human pancreatic beta cells (the cells which go wrong in diabetes). These make it easier for scientists to study diabetes in the lab.
- Towards safer medicines: The WEB-RADR project has developed a smartphone app that allows patients, carers and healthcare professionals to quickly and easily report side effects of medicines.
- Faster drug development: The European Lead Factory has created a unique drug discovery platform that scientists can apply to use for their own research. Users report that the results have significantly accelerated their drug development programmes.
- Promoting patient involvement in research: The EUPATI project has compiled an online, multilingual educational toolbox (www.eupati.eu) for patients who want to know more about, or get involved in, medicines research and development.